Brought to you by 
Atrix licenses Leuprogel products to MediGene in Europe
03 Apr 2002
Executive Summary
German cancer and cardiology drug company MediGene licensed European marketing rights to three of Atrix Laboratories' Leuprogel (leuprolide; LHRH agonist) products, all indicated for advanced prostate cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Atrix licenses Leuprogel products to MediGene in Europe
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice